The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2022
The AGM 2022 resolved that a nominating committee should be appointed in accordance with the following: “The nominating committee shall consist of representatives for the three largest shareholders in terms of votes as of 30 September each year. If any of these shareholders refrains from appointing a representative, the following shareholders shall, in the order of magnitude, be given the opportunity to appoint a representative until three members have been appointed. The names of the members in the nominating committee must be published by the company no later than six months prior to the coming AGM. The shareholder representative who represents the largest shareholder, shall be appointed chairman of the nominating committee, unless the nominating committee decides otherwise”.
The nominating committee has been constituted in accordance with the resolution adopted by the AGM 2022. The nominating committee consists of Ivar Nordqvist, Arne Ferstad representing Myrlid AS and Marcus Isaksson representing Thoren Tillväxt AB.
The nominating committee’s tasks include submitting proposals to the AGM regarding:
• Chairman of the AGM
• Election of board members
• Chairman of the board of directors
• Remuneration to the board of directors including the chairman
• Election of auditor and remuneration to the auditor
• Rules of procedure for the nominating committee
Contacts
Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com
Bert Junno, Chairman of the board
Phone: +46 (0)707 77 22 09
bert.junno@combigene.com
www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, info@fnca.se.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714